Novo Nordisk on Wednesday reported better-than-expected quarterly sales of its popular Wegovy weight-loss drug and narrowed ...

Novo Nordisk shares were up Wednesday following an earnings report that showed continued sales growth of its obesity drug.

Novo Nordisk A/S’s sales of blockbuster weight-loss drug Wegovy beat expectations in the third quarter, a potential relief ...

The Danish company’s share price rise of 7 per cent this year lags far behind its rival Eli Lilly’s 36 per cent, as the US company has gradually increased its share of the obesity and diabetes market ...

GLP-1 agonist Wegovy (semaglutide) brought in DKK 17.3 billion ($2.49 billion) in the period, restoring earlier levels of ...

Novo’s obesity drug sales nearly doubled outside the U.S. during the quarter as global demand continued to rise.

Novo Nordisk reported strong sales for its weight-loss drug Wegovy, surpassing analyst expectations and calming investor ...

Viking Therapeutics has announced its oral formulation of VK2735 has scored in a Phase I trial at ObesityWeek 2024.

With the FDA approval of the first specific drug for Metabolic Associated Steatohepatitis (MASH) in March this year, Madrigal’s Rezdiffra is a pioneer in a market set for rapid change. | With the FDA ...

Only 13 states currently offer Medicaid coverage for GLP-1 drugs, but the number of prescriptions and overall spending has ...

Here are the key points about Viking Therapeutics' oral obesity drug VK2735: Early-Stage Trial Results: All doses of VK2735 ...